Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Diabetes Insipidus I: Introduction

Diabetes Insipidus I: Introduction

Definition Diabetes insipidus is a disorder marked by the production of large amounts of dilute urine because of impaired vasopressin production, release, or kidney response. The lack of effective vasopressin action limits water reabsorption in the renal collecting ducts, which leads to excessive urinary water loss and intense thirst.Clinical PresentationIndividuals with diabetes insipidus report persistent thirst and very high urine output. In severe cases, fluid intake can reach up to 20...

Diabetes Insipidus II: Pathophysiology

Diabetes Insipidus II: Pathophysiology

Normally, water balance is maintained through three interconnected mechanisms: the hypothalamic thirst center, the synthesis and release of antidiuretic hormone (ADH, or vasopressin), and the kidneys' responsiveness to this hormone. ADH is synthesized in the hypothalamus, released from the posterior pituitary, and acts on the distal nephron, allowing water reabsorption and concentrated urine production.Diabetes Insipidus and Its TypesIn diabetes insipidus (DI), this regulatory system is...

Adrenergic Agonists: Therapeutic Uses

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...

Intrauterine Drug Delivery Systems

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...

Adrenergic Agonists: Therapeutic Classification

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...

Antihypertensive Drugs: Action of Diuretics

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various tubules...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Activation of the hemostatic mechanism during thrombolysis in patients with unstable angina pectoris.

Blood·1995

Same author

Determinants of plasma factor VIIa levels in humans.

Blood·1995

Same author

Heightened thrombin formation but normal plasma levels of activated factor VII in patients with acute coronary syndromes.

Arteriosclerosis, thrombosis, and vascular biology·1995

Same author

Purinoceptors on blood platelets: further pharmacological and clinical evidence to suggest the presence of two ADP receptors.

British journal of haematology·1995

Same author

Platelet von Willebrand factor abnormalities in myeloproliferative syndromes.

American journal of hematology·1995

Same author

Hypercoagulability in centenarians: the paradox of successful aging.

Blood·1995

Search research articles

Related Experiment Video

Updated: Jul 8, 2026

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Published on: June 21, 2013

Desmopressin: an historical introduction.

¹Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Department of Medicine and Medical Specialties, University of Milan, Italy. pmmannucci@libero.it

Haemophilia : the Official Journal of the World Federation of Hemophilia

|January 5, 2008

Summary

Desmopressin is now a key treatment for bleeding disorders like mild hemophilia and von Willebrand disease. This review details its journey to becoming an effective hemostatic agent.

More Related Videos

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Related Experiment Videos

Last Updated: Jul 8, 2026

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Culturing Primary Rat Inner Medullary Collecting Duct Cells

Published on: June 21, 2013

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

Area of Science:

Pharmacology
Hematology
Medical Chemistry

Background:

Desmopressin's development as a hemostatic agent is crucial for managing bleeding disorders.
Mild hemophilia and von Willebrand disease present unique challenges in hemostasis.

Purpose of the Study:

To review the developmental pathway of desmopressin for hemostatic applications.
To highlight desmopressin's role in expanding treatment options for specific bleeding conditions.

Main Methods:

Literature review of desmopressin's development and clinical application.
Analysis of pharmacological mechanisms of action.
Synthesis of historical and clinical data.

Main Results:

Desmopressin has been successfully developed as a pharmacological hemostatic agent.
The drug is effective in treating and preventing bleeding in patients with mild hemophilia.
It also provides a viable option for managing von Willebrand disease.

Conclusions:

Desmopressin significantly broadens the therapeutic armamentarium for hemostasis.
Its development represents a major advancement in managing bleeding risks in specific hematological conditions.